Pliant Therapeutics (PLRX)

• Market cap: $821M
• 1 day: 1.12%
• 5 days: -7.16%
• 1 month: 0.22%
• 3 months: 19.06%
• 6 months: 18.85%
• Year to date: -24.89%
• 1 year: -27.16%
• 5 years: -36.67%
• 10 years: -36.67%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 166

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

81% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 32

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

6% more funds holding

Funds holding: 143 [Q2] → 151 (+8) [Q3]

5% more capital invested

Capital invested by funds: $694M [Q2] → $727M (+$32.9M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

2.35% less ownership

Funds ownership: 107.03% [Q2] → 104.68% (-2.35%) [Q3]

74% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $4.99M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $38 182% upside
• Avg. target: $38 182% upside
• High target: $38 182% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 50% 1-year accuracy 74 / 148 met price target

182% upside $38

Buy Reiterated

8 Nov 2024